Towa Pharmaceutical to ship Japan-made generics to US: CEO

Pharmaceuticals Towa Pharmaceutical to ship Japan-made generics to US: CEO Company eyes shift to high-value-added injectable drugs, Yoshida says Towa gained a U.S. sales network from the 2020 acquisition of a Spanish drugmaker. (Photo by Nikkei) NANAKO TAKEUCHI November 10, 2026 00:40 JST OSAKA -- Towa Pharmaceutical plans to start exporting generic injectable drugs to the U.S. as early as 2028, with the company seeking to leverage its advanced quality control capabilities to gain a foothold in the competitive American market. Read Next Pharmaceuticals Takeda bets on blockbuster drug trio to generate $11bn in peak sales Pharmaceuticals Takeda debuts narcolepsy drug targeting root cause, capping 15-year effort Pharmaceuticals Global pharma firms walk back innovative drug investments in Japan Companies Japan's Terumo takes $610m hit after losing US customer for plasma device Pharmaceuticals Shionogi to buy US-based IntraBio for $2bn to expand rare disease drug business Pharmaceuticals Half of new US-approved drugs remain unavailable to Japanese patients Science Japan aims to develop 'next-gen' iPS cells for strokes and kidney failure Pharmaceuticals Roche-owned Chugai Pharma to ramp up in-house output with 50% capex boost Pharmaceuticals Japan aims to ensure domestic vaccine production capacity for next crisis Pharmaceuticals Mitsui to help speed cancer drug research in Asia with patient database Latest on Pharmaceuticals Pharmaceuticals Takeda bets on blockbuster drug trio to generate $11bn in peak sales Pharmaceuticals Takeda debuts narcolepsy drug targeting root cause, capping 15-year effort Pharmaceuticals Global pharma firms walk back innovative drug investments in Japan Sponsored Content About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.